Bio-Techne and Oxford Nanopore expand agreement to accelerate development of genetics portfolio through 2032
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit
Establishes a framework to define and propose future portfolios
Extends collaboration through 2032, reinforcing Bio-Techne’s diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies
Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced a significant enhancement to its agreement with Oxford Nanopore Technologies. The expanded agreement broadens Bio-Techne’s ability to develop a portfolio of genetic products on Oxford Nanopore Technologies' platform and extends the collaboration through 2032.
Building upon the successful launch of the AmplideX® Nanopore Carrier Plus Kit in March 2025, the enhanced collaboration streamlines coordination on the development and commercialisation of a broader portfolio of targeted enrichment sequencing kits for the screening and potential diagnosis of heritable genetic disorders.
“This expanded agreement underscores our commitment to advancing genetic testing solutions that simplify workflows and deliver richer insights for laboratories worldwide,” said Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. “By deepening our collaboration with Oxford Nanopore, we are accelerating innovation in diagnostics and creating a foundation for future portfolios.”
“We’re pleased to expand our collaboration with Bio-Techne to bring new genetic testing solutions to laboratories worldwide. By combining Bio-Techne’s diagnostics expertise and innovations with our advanced molecular sensing platform, together we can make testing faster, simpler, and more accessible,” said Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies.
